|
Products, Technologies, Markets and
Opportunities in
Diabetes Management Worldwide,
2005-2015
Report D500
· 276 pages
· 82 Exhibits
· 96 Company Profiles
· February 2006
· Report #D500
Worldwide report on products, trends, competitors
and markets for diabetes management.
This report details the worldwide
incidence and prevalence by country/region of Type 1 and Type 2 diabetes and
details the current and projected market for diagnostic and therapeutic
products in the management of diabetes, including anti-diabetic drugs,
alternative insulin types, blood glucose monitoring (including
continuous
monitoring devices), insulin pumps, and other established and emerging
products in diabetes management. The report provides an emphasis of
detail on the status of development of novel products including noninvasive
monitoring, oral/inhaled/other insulin delivery. The report details the
clinical and technology developments underlying this huge and evolving
worldwide market, with data on products in development and on the market;
market size and forecast; competitor market shares; competitor profiles; and
market opportunity. Separate size, growth and competitor share data
are presented for the U.S., individual western European countries (Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom),
and Japan. The report profiles active companies including detailed
profile information on major competitors, brief profiles of companies with
less sizeable current or potential positions in the market, plus
additional profiles of companies with novel or advanced research activities
in the market.
The report establishes
the current worldwide market size for major technology segments as a
baseline for and projecting growth in the market over a ten-year forecast.
The report also assesses and projects the composition of the market as
technologies gain or lose relative market performance over this period.
Purchase
Executive Summary only, PDF download -- $275.00
Products & Technologies Covered:
Table of Contents
EXECUTIVE SUMMARY
Some Diabetes Basics
A Large and Growing Market
A Many-Sided Market
Pharmaceuticals for Diabetes
Insulin
Oral Anti-diabetic Drugs
The Pharmaceutical Diabetes Market
Insulin Administration Devices
Medical Devices for Diabetes
Total Diabetes Market
Regional Segmentation
Market Growth
The Diabetes Industry
Pharmaceutical Companies
Medical Device Companies
Section 1:
ABOUT DIABETES
1.1 What is Diabetes?
1.2 Blood Sugar Regulation
1.2.1 Insulin
1.3 Main Types of Diabetes
1.3.1 Type 1 Diabetes
1.3.2 Type 2 Diabetes
1.3.3 Gestational Diabetes
1.3.4 Obesity-Related type 2
Diabetes in Children.
1.3.5 Mature-onset Diabetes of the
Young (MODY)
1.3.6 Other Diabetic States
1.4 Diagnosis
1.4.1 Glucose Tests
1.4.2 Official Criteria
1.4.3 Differential Diagnosis
1.4.3.1 Type 1 Diabetes
1.4.3.2 Type 2 Diabetes
1.5 Current Treatment
1.5.1 Type 1 Diabetes
1.5.2 Type 2 Diabetes
1.5.3 Diet
1.6 Future Treatment Approaches
1.7 Treatment Monitoring
1.7.1 Blood Sugar Control
1.7.2 The Diabetes Control and
Complications Trial
1.7.3 Glycated haemoglobin (HbA1c)
1.7.4 Fructosamine
1.8 Incidence and Prevalence of Diabetes
(Type 1 & Type 2)
1.8.1 Worldwide
1.8.2 USA
1.8.3 Japan
1.8.4 Europe
1.9 Diabetic Complications
1.9.1 Retinopathy
1.9.2 Neuropathy
1.9.3 Nephropathy
1.10 Metabolic Syndrome
Section 2:
Products Used in Diagnosis and Monitoring
2.1 Blood Glucose Monitoring Devices:
Suppliers and Products
2.1.1 Lancets
2.1.2 Blood Sampling Devices
2.1.2.1 Bayer Diagnostics
2.1.2.2 Becton Dickinson
2.1.2.3 Cell Robotics
2.1.2.4 LifeScan
2.1.2.5 Roche Diagnostics
2.1.3 Blood Glucose Monitors
2.1.3.1 77 Elektronica Kft
2.1.3.2 Abbott Laboratories
2.1.3.3 Acon Laboratories Inc.
2.1.3.4 Apex Biotechnology Corp.
2.1.3.5 Bayer Corporation
2.1.3.6 Becton Dickinson & Co
2.1.3.7 Belbiosens
2.1.3.8 Cygnus Inc – Animas Corp
2.1.3.9 Diagnostic Devices Inc.
2.1.3.10 Eumed Biotechnology Co.
Ltd.
2.1.3.11 HMD Bio Medical
2.1.3.12 Glucoplus Inc
2.1.3.13 HemoCue AB
2.1.3.14 Home Diagnostics Inc
2.1.3.15 Hypoguard
2.1.3.16 LifeScan Inc
2.1.3.17 Medtronic MiniMed
2.1.3.18 Polymer Technology Systems
Inc.
2.1.3.19 QuestStar Medical Inc
2.1.3.20 Roche
2.1.3.21 TaiDoc Technology
Corporation
2.1.3.22 US Diagnostics Inc.
2.1.4 New Developments in Glucose
Testing
2.2 ‘Artificial Pancreas’
2.2.1 Medtronic
2.2.2 Roche
2.2.3 Abbott
2.2.4 Novo Nordisk/LifeScan
2.3 Other Testing Approaches
2.3.1 Hemoglobin A1c
2.3.1.1 Hemoglobin A1c Meters
2.3.1.2 Hemoglobin A1c Kits
2.4 Software
Programs for Diabetes Monitoring.
2.4.1 Web Software
2.4.2 Commercial Software
Section 3:
Products Used in Treatment
3.1 Insulin
3.1.1 History
3.1.1.1 Bovine and Porcine
Insulin
3.1.1.2 Humanized Insulin
3.1.2 Companies Supplying Insulin
3.1.2.1 Eli Lilly
3.1.2.2 Aventis
3.1.2.3 Novo Nordisk
3.1.2.4 Some Other Suppliers
3.1.3 Insulin Delivery
3.1.3.1 Syringes
3.1.4 Insulin Syringe
Manufacturers
3.1.4.1 Pens
3.1.4.2 Manufacturers of Insulin
Pens
3.1.4.3 Injectors
3.1.4.4 Injector Manufacturers
3.1.5 Inhaled insulin
3.1.6 Pfizer/Sanofi-Aventis/Nektar
Therapeutics
3.1.6.1 Lilly/Alkermes
3.1.6.2 Novo Nordisk/Aradigm
3.1.6.3 MannKind
3.1.7 Insulin Pumps
3.1.7.1 What is an Insulin Pump?
3.1.7.2 The Infusion Set
3.1.7.3 Candidates for Pump
Therapy
3.1.8 Companies Supplying Insulin
Pumps
3.1.8.1 Animas Corporation
3.1.8.2 DANA Diabecare
3.1.8.3 Medtronic MiniMed
3.1.8.4 Nipro Diabetes Systems
3.1.8.5 Roche Disetronic
3.1.8.6 Smiths Medical
3.2 Oral Hypoglycaemic Drugs
3.2.1 Sulfonylureas
3.2.2 Biguanides
3.2.3 Alpha-Glucosidase Inhibitor
3.2.4 Thiazolidinediones
3.2.5 Prandial Glucose Regulators
3.2.6 Incretin Mimetics
3.2.7 Amylin Mimetic
3.2.8 New Products Now in R&D
Section 4:
Novel Approaches to Diabetes Management
4.1 Pancreas Transplants
4.2 Islet Cell Transplants
4.2.1 Edmonton Protocol
4.2.2 Improving ICT
4.2.3 Living-Donor Islet Cell
Transplant
4.3 Stem Cell Developments
4.3.1 ADA Endorsement
4.3.2 Stem Cell Research at EASD
2005
4.3.2.1
Adult Stem Cells
4.4 Antibody Treatment
4.5 Vaccines
4.5.1 Diamyd Medical
4.5.2 DeveloGen
4.6 Genetic Approaches
4.6.1 Genetic Testing
4.6.2 Small-interfering RNA (SiRNA)
4.7 Novel Drugs
4.7.1 DDP-IV Inhibitors
4.7.2 Other Drugs
4.7.3 All-in-one Treatment for
Type 2 Diabetes?
4.8 Continuous Glucose Monitoring
4.8.1 Electroenzymatic Sensor
4.8.2 Optical Glucose Sensor
4.8.3 Sensor Based on Carbon
Nanotubes
Section 5:
The Diabetes Market
5.1 Global Market
5.1.1 Size
5.1.2 Growth
5.1.3 Regional Segmentation
5.2 Market Analysis by Product Category
5.2.1 Monitoring Products
5.2.1.1 Major Suppliers
5.2.2 Insulins and Insulin
Delivery Devices
5.2.2.1 Major Suppliers
5.2.2.1.1
Insulin
5.2.2.1.2
Syringes and Other
Insulin Administration Devices
5.2.2.1.3
Insulin Pumps
5.2.3 Oral Antidiabetic Drugs
5.2.3.1 Major Suppliers
5.3 Trends
5.4 Main National Markets
5.4.1 Belgium
5.4.2 Denmark
5.4.3 France
5.4.4 Germany
5.4.5 Italy
5.4.6 Japan
5.4.7 Netherlands
5.4.8 Norway
5.4.9 Spain
5.4.10 Sweden
5.4.11 United Kingdom
5.4.12 USA
Section 6:
Company Profiles
6.1 Leading Companies
6.1.1 Abbott Laboratories
6.1.1.1 Overview
6.1.1.2 Diabetes Products
6.1.1.3 Pipeline
6.1.1.4 Financials
6.1.2 Bayer
6.1.2.1 Overview
6.1.2.2 Diabetes Products
6.1.2.2.1
Ascensia Blood
Glucose Monitoring
6.1.2.3 Financials
6.1.3 Becton Dickinson
6.1.3.1 Overview
6.1.3.2 Diabetes Products
6.1.3.2.1
Insulin Injection
Devices
6.1.3.2.2
Glucose monitoring
products
6.1.3.3 Financials
6.1.4 Bristol-Myers Squibb
6.1.4.1 Overview
6.1.4.1.1
Problems with
Generics
6.1.4.2 Diabetes Products
6.1.4.3 Financials
6.1.5 Eli Lilly
6.1.5.1 Overview
6.1.5.2 Diabetes Products
6.1.5.3 Financials
6.1.5.4 Pipeline
6.1.6 Glaxo SmithKline
6.1.6.1 Overview
6.1.6.2 Diabetes products
6.1.6.3 Financials
6.1.6.4 Pipeline
6.1.7 Johnson & Johnson
6.1.7.1 Overview
6.1.7.2 Diabetes Products
6.1.7.3 Financials
6.1.8 Medtronic
6.1.8.1 Overview
6.1.8.2 Diabetes Products
6.1.8.2.1
Paradigm 512/712
insulin pump
6.1.8.2.2
Paradigm 515/715
insulin pump
6.1.8.2.3
CGMS System Gold
6.1.8.3 Financials
6.1.8.4 Pipeline
6.1.9 Merck KgaA
6.1.9.1 Overview
6.1.9.2 Diabetes Product
6.1.9.3 Financials
6.1.10 Novartis
6.1.10.1 Overview
6.1.10.2 Diabetes Product
6.1.10.3 Financials
6.1.10.4 Pipeline
6.1.11 Novo Nordisk
6.1.11.1 Overview
6.1.11.2 Diabetes Products
6.1.11.2.1
Pharmaceuticals
6.1.11.3 Financials
6.1.11.4 Pipeline
6.1.12 Pfizer
6.1.12.1 Overview
6.1.12.2 Diabetes Products
6.1.12.3 Financials
6.1.12.4 Pipeline
6.1.13 Roche
6.1.13.1 Overview
6.1.13.2 Diabetes Products
6.1.13.2.1
Accutrend GC/GCT
6.1.13.3 Financials
6.1.13.4 Pipeline
6.1.14 Sanofi-Aventis
6.1.14.1 Overview
6.1.14.2 Diabetes Products
6.1.14.3 Financials
6.1.14.4 Pipeline
6.1.15 Takeda
6.1.15.1 Overview
6.1.15.2 Diabetes Products
6.1.15.3 Financials
6.1.15.4 Pipeline
6.1.15.4.1
TAK-559
6.1.15.4.2
TAK-654
6.2 Other Companies
6.2.1 77 Elektronica
6.2.2 Acon Laboratories
6.2.3 Activa
6.2.4 AdipoGenix
6.2.5 AgaMatrix
6.2.6 AiMedics Pty Ltd
6.2.7 Alkermes Inc.
6.2.8 Amylin
6.2.9 Animas Corp.
6.2.10 Antares Pharma
6.2.11 Apex Biotechnology Ltd
6.2.12 Aradigm
6.2.13 Arena Pharmaceuticals
6.2.14 B Braun
6.2.15 Belbiosens
6.2.16 Benitec Limited
6.2.17 Biocon
6.2.18 Bioject Medical Technologies
Inc.
6.2.19 BioSafe Medical Technologies
Inc
6.2.20 Biovitrum
6.2.21 Cell Robotics International,
Inc
6.2.22 ChemGenex Pharmaceuticals Ltd
6.2.23 Dana Diabecare USA
6.2.24 Devgen NV
6.2.25 Dexcom Inc
6.2.26 Diabetes Technologies Inc.
6.2.27 Diagnostic Devices Inc.
6.2.28 Diosynth
6.2.29 EnGene
6.2.30 Equidyne Corporation
6.2.31 Eumed Biotechnology Co. Inc
6.2.32 FivePrime Therapeutics
6.2.33 FlexSite Diagnostics
6.2.34 Fluent Biomedical Inc
6.2.35 GlucoLight Corporation
6.2.36 Glucon Medical Ltd
6.2.37 Glucoplus Inc
6.2.38 GluMetrics LLC
6.2.39 Hemocue AB
6.2.40 Hitachi Ltd
6.2.41 HMD Biomedical
6.2.42 Home Diagnostics Inc
6.2.43 HypoGuard
6.2.44 Infratec Inc
6.2.45 InLight Solutions Inc
6.2.46 Integrity Applications Ltd
6.2.47 Kumetrix Inc
6.2.48 Laboratorios Beta
6.2.49 LifeTrac Systems Inc
6.2.50 Ligand Pharmaceuticals Inc
6.2.51 MannKind
6.2.52 Menarini
6.2.53 Metabolex
6.2.54 Metrika Inc.
6.2.55 Nektar Therapeutics
6.2.56 Nipro Diabetes Systems Inc
6.2.57 Owen Mumford
6.2.58 Palco Laboratories
6.2.59 Pelikan Technologies
6.2.60 Pindi Products
6.2.61 Polymer Technology Systems
Inc
6.2.62 Provalis plc
6.2.63 QuestStar Medical Inc
6.2.64 Quotient Diagnostics Ltd
6.2.65 Rosch AG Medizintechnik
6.2.66 Sanwa Kagaku Kenkyusho Co.
Ltd.
6.2.67 SenSys Medical
6.2.68 Laboratoires Servier
6.2.69 Sirna Therapeutics
6.2.70 Smiths Medical
6.2.71 Sontra Medical Corporation
6.2.72 SpectRx Inc
6.2.73 TaiDoc Technology Corporation
6.2.74 Terumo Medical Corporation
6.2.75 Theratechnologies Inc.
6.2.76 TolerRx Inc.
6.2.77 US Diagnostics Inc
6.2.78 Vaxine Pty Ltd.
6.2.79 VeraLight Inc.
6.2.80 Vivo Medical Inc.
6.2.81 Wockhardt Ltd
Appendix: Company Addresses
List of Exhibits
Exhibit ES-1: Total Diabetes Market, 2004
Exhibit ES-2: Regional Segmentation of
Diabetes Market
Exhibit 1.1: Threshold Glucose Levels
Indicative of Diabetes/Hyperglycemia (mmol/L)
Exhibit 1-2: Main Brands and Types of Insulin
Exhibit 1-3: Oral Diabetes Treatments
Exhibit 1-4: Prevalence of Diabetes by Region
(Age 20-79 Years)
Exhibit 1-5: Differences in the Prevalence of
Type 2 Diabetes Among Selected Ethnic Groups, 2003
Exhibit 1-6: Prevalence of Diabetes in USA,
2003
Exhibit 1-7: Incidence of Type 1 Diabetes in
Western European countries (Cases per 100,000 Child Population, per Annum)
Exhibit 1-8: Type 1 Diabetes Incidence Growth
Rates in Selected European Countries
Exhibit 1-8: Estimated Prevalence of Type 2
Diabetes in Western European Countries
Exhibit 2-1: International Suppliers of Blood
Lancets
Exhibit 2-2: Blood Glucose Meters
Exhibit 2-3: Research Projects in Glucose
Monitoring
Exhibit 2-4: Commercial Software Programs for
Windows and Macintosh
Exhibit 3-1: Major Brands of Insulin
Exhibit 3-2: Manufacturers of Insulin Pens
Exhibit 3-3: Manufacturers of Insulin Pups
Exhibit 3-4: Sulfonylureas
Exhibit 3-5: Oral Hypoglycemics
Exhibit 5-1: Prevalence of Diabetes Mellitus,
by Selected Country, 2003 and 2025 (Percent of Population Age 20-79)
Exhibit 5-2: Global Diabetes Market 2004
Exhibit 5-3: Relative Market Size of Major
Regional Diabetes Markets; USA, Western Europe and Japan
Exhibit 5-4: Glucose Monitors: Leading
Companies 2004
Exhibit 5-5: Market Shares, Insulin,
Worldwide, 2004
Exhibit 5-6: Market Shares, Insulin Syringes,
Worldwide, 2004
Exhibit 5-7: Market Shares, Insulin Pens,
Worldwide, 2004
Exhibit 5-8: Market Shares, Insulin Pumps,
Worldwide, 2004
Exhibit 5-9: Market Shares, Oral Antidiabetic
Drugs, Worldwide, 2004
Exhibit 5-10: Market for Insulin and Other
Diabetes Medications, Belgium, 2003-2015
Exhibit 5-11: Market for Glucose Meters,
Belgium, 2003-2015
Exhibit 5-12: Market for Insulin Pumps,
Belgium, 2003-2015
Exhibit 5-13: Market for Insulin and Other
Diabetes Medications, Denmark, 2003-2015
Exhibit 5-14: Market for Glucose Meters,
Denmark, 2003-2015
Exhibit 5-15: Market for Insulin and Other
Diabetes Medications, France, 2003-2015
Exhibit 5-16: Market for Glucose Meters,
France, 2003-2015
Exhibit 5-17: Market for Insulin Pumps,
France, 2003-2015
Exhibit 5-18: Market for Insulin and Other
Diabetes Medications, Germany, 2003-2015
Exhibit 5-19: Market for Glucose Meters,
Germany, 2003-2015
Exhibit 5-20: Market for Insulin Pumps,
Germany, 2003-2015
Exhibit 5-21: Market for Insulin and Other
Diabetes Medications, Italy, 2003-2015
Exhibit 5-22: Market for Glucose Meters,
Italy, 2003-2015
Exhibit 5-23: Market for Insulin Pumps, Italy,
2003-2015
Exhibit 5-24: Market for Insulin and Other
Diabetes Medications, Japan, 2003-2015
Exhibit 5-25: Market for Glucose Meters,
Japan, 2003-2015
Exhibit 5-26: Market for Insulin Pumps, Japan,
2003-2015
Exhibit 5-27: Market for Insulin and Other
Diabetes Medications, Netherlands, 2003-2015
Exhibit 5-28: Market for Glucose Meters,
Netherlands, 2003-2015
Exhibit 5-29: Market for Insulin Pumps,
Netherlands, 2003-2015
Exhibit 5-30: Market for Insulin and Other
Diabetes Medications, Norway, 2003-2015
Exhibit 5-31: Market for Glucose Meters,
Norway, 2003-2015
Exhibit 5-32: Market for Insulin Pumps,
Norway, 2003-2015
Exhibit 5-33: Market for Insulin and Other
Diabetes Medications, Spain, 2003-2015
Exhibit 5-34: Market for Glucose Meters,
Spain, 2003-2015
Exhibit 5-35: Market for Insulin Pumps, Spain,
2003-2015
Exhibit 5-36: Market for Insulin and Other
Diabetes Medications, Sweden, 2003-2015
Exhibit 5-37: Market for Glucose Meters,
Sweden, 2003-2015
Exhibit 5-38: Market for Insulin Pumps,
Sweden, 2003-2015
Exhibit 5-39: Market for Insulin and Other
Diabetes Medications, United Kingdom, 2003-2015
Exhibit 5-40: Market for Glucose Meters,
United Kingdom, 2003-2015
Exhibit 5-41: Market for Insulin Pumps, United
Kingdom, 2003-2015
Exhibit 5-42: Market for Insulin and Other
Diabetes Medications, United States, 2003-2015
Exhibit 5-43: Market for Glucose Meters,
United States, 2003-2015
Exhibit 5-44: Market for Insulin Pumps, United
States, 2003-2015
Exhibit 6-1: Abbott Laboratories Financial
Data, 2004
Exhibit 6-2: Bayer Group Financials, 2004
Exhibit 6-3: Becton Dickinson Financials, 2004
Exhibit 6-4: Bristol-Myers Squibb Financials,
2004
Exhibit 6-5: Eli Lilly Financials, 2004
Exhibit 6-6: Glaxo SmithKline Financials, 2004
Exhibit 6-7: Glaxo SmithKline Diabetes
Products in Research Pipeline
Exhibit 6-8: J&J Medical Devices and
Diagnostics Financials, 2004
Exhibit 6-9: Medtronic Financials, 2004
Exhibit 6-10: Merck KGaA Financials, 2004
Exhibit 6-11: Novartis Financials, 2004
Exhibit 6-12: Novo Nordisk Financials, 2004
Exhibit 6-13: Pfizer leading products
Exhibit 6-14: Pfizer Financials, 2004
Exhibit 6-15: Roche Financials, 2004
Exhibit 6-16: Sanofi Aventis, Leading Products
2004
Exhibit 6-17: Sanofi-Aventis Financials, 2004
Exhibit 6-18: Takeda Leading Products
Exhibit 6-19: Takeda Financials, 2005
|
